Prediction model with blood test significantly improves lung cancer risk assessment compared to current guidelines
MD Anderson News Release
January 07, 2022
A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer screening than the current U.S. recommendation, according to a study published today in the Journal of Clinical Oncology led by researchers from The University of Texas MD Anderson Cancer Center.
A personalized lung cancer risk assessment, combining a blood test based on a four-marker protein panel developed at MD Anderson and an independent model (PLCOm2012) that accounts for smoking history, was more sensitive and specific than the 2021 and 2013 U.S. Preventive Services Task Force (USPSTF) criteria.
The study included participants from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial with at least a 10 pack-year smoking history.
If implemented, the blood test plus model would have identified 9.2% more lung cancer cases for screening and reduced referral to screening among non-cases by 13.7% compared to the 2021 USPSTF criteria.
If implemented, the blood test plus model would have identified 9.2% more lung cancer cases for screening and reduced referral to screening among non-cases by 13.7% compared to the 2021 USPSTF criteria.
“We recognize that a small percentage of people who are eligible for lung cancer screening through an annual low-dose CT scan are actually getting screening.
Moreover, CT screening is not readily available in most countries.
So, our goal, for many years, has been to develop a simple blood test that can be used first to determine need for screening and make screening for lung cancer that much more effective,”
said Sam Hanash, M.D., Ph.D., professor of Clinical Cancer Prevention and leader of the McCombs Institute for the Early Detection and Treatment of Cancer.
“Our study shows for the first time that a blood test could be useful to determine who may benefit from lung cancer screening.”
The USPSTF recommends that adults at high risk for lung cancer receive a low-dose CT scan each year, which was shown to reduce lung cancer deaths in the 2011 National Lung Screening Trial (NLST).
The 2021 USPSTF criteria applies to adults age 50 to 80 who have at least a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
Hanash and colleagues developed a blood test incorporating biomarkers that they previously identified as predictive of lung cancer risk.
A multicenter team used a blinded study to evaluate the performance of this four-protein marker panel in combination with the PLCOm2012 model, which was independently developed and validated to predict a six-year risk for lung cancer among individuals who currently smoke or smoked formerly.
“When we began work on a blood test, there were many different types of markers,” Hanash said.
“We’ve done multiple analyses over the past decade to come up with a cost-effective test that’s simple, yet robust, which has been the guiding principle of our research.”
To test the combination of blood markers with the PLCOm2012 model, the researchers analyzed more than 10,000 biospecimens from the PLCO study, including 1,299 blood samples collected from 552 individuals who developed lung cancer and 8,709 samples collected from 2,193 people who did not develop lung cancer.
Among individuals with at least a 10 pack-year smoking history, the combined blood test with PLCOm2012 model showed overall improved sensitivity (88.4% versus 78.5%) and improved specificity (56.2% versus 49.3%), compared to the current USPSTF criteria.
If implemented, the combined personalized risk assessment would have identified 105 of the 119 people in the PLCO intervention arm who received a lung cancer diagnosis within one year.
“A blood test would identify people who could benefit from lung cancer screening but are not eligible today,” Hanash said. “Tens of millions of people worldwide could benefit from lung cancer screening. If you can improve screening eligibility by even 5%, that is incredibly impactful.”
While the blood test could be implemented as a lab-developed test in the near future, Food and Drug Administration approval likely would require evaluation through a prospective clinical trial.
The study was supported by the National Institutes of Health and National Cancer Institute (U01CA194733, U01CA213285, U24CA086368, U01 CA200468), the Cancer Prevention & Research Institute of Texas and Lyda Hill Philanthropies.
Additional research support was provided by the Lung Cancer Moon Shot®, part of MD Anderson’s Moon Shots Program®, a collaborative effort designed to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
Hanash is an inventor on a patent application related to the blood test. A complete list of co-authors, their affiliations and their disclosures is included in the paper.
Names mentioned
Sam Hanash, M.D., Ph.D., professor of Clinical Cancer Prevention and leader of the McCombs Institute for the Early Detection and Treatment of Cancer.
ORIGINAL PUBLICATION
Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment
Journal of Clinical Oncology
Johannes F. Fahrmann, PhD1; Tracey Marsh, PhD2; Ehsan Irajizad, PhD1,3; Nikul Patel, MS1; Eunice Murage, PhD1; Jody Vykoukal, PhD1; Jennifer B. Dennison, PhD1; Kim-Anh Do, PhD3; Edwin Ostrin, MD, PhD4; Margaret R. Spitz, MPH5; Stephen Lam, MD6; Sanjay Shete, PhD7; Rafael Meza, PhD8; Martin C. Tammemägi, PhD9,10; Ziding Feng, PhD2; and Samir M. Hanash, MD, PhD1
1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX
2Biostatistics Program, Fred Hutchinson Cancer Research Center, Seattle, WA
3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Medicine, Baylor College of Medicine, Houston, TX
6Department of Integrative Oncology, British Columbia Cancer Research Institute, Vancouver, British Columbia, Canada
7Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Epidemiology, University of Michigan, School of Public Health, Ann Arbor, MI
9 Prevention and Cancer Control, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada
10Department of Health Sciences, Brock University, St Catharines, Ontario, Canada
- J.F.F., T.M., and E.I. contributed equally to this work.
ABSTRACT
PURPOSE
To investigate whether a panel of circulating protein biomarkers would improve risk assessment for lung cancer screening in combination with a risk model on the basis of participant characteristics.
METHODS
A blinded validation study was performed using prostate lung colorectal ovarian (PLCO) Cancer Screening Trial data and biospecimens to evaluate the performance of a four-marker protein panel (4MP) consisting of the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment in combination with a lung cancer risk prediction model (PLCOm2012) compared with current US Preventive Services Task Force (USPSTF) screening criteria. The 4MP was assayed in 1,299 sera collected preceding lung cancer diagnosis and 8,709 noncase sera.
RESULTS
The 4MP alone yielded an area under the receiver operating characteristic curve of 0.79 (95% CI, 0.77 to 0.82) for case sera collected within 1-year preceding diagnosis and 0.74 (95% CI, 0.72 to 0.76) among the entire specimen set. The combined 4MP + PLCOm2012 model yielded an area under the receiver operating characteristic curve of 0.85 (95% CI, 0.82 to 0.88) for case sera collected within 1 year preceding diagnosis. The benefit of the 4MP in the combined model resulted from improvement in sensitivity at high specificity. Compared with the USPSTF2021 criteria, the combined 4MP + PLCOm2012 model exhibited statistically significant improvements in sensitivity and specificity. Among PLCO participants with ≥ 10 smoking pack-years, the 4MP + PLCOm2012 model would have identified for annual screening 9.2% more lung cancer cases and would have reduced referral by 13.7% among noncases compared with USPSTF2021 criteria.
CONCLUSION
A blood-based biomarker panel in combination with PLCOm2012 significantly improves lung cancer risk assessment for lung cancer screening.
© 2022 by American Society of Clinical Oncology
CONTEXT
Key Objective
- Can a combination of a blood-based four-marker protein panel with the prostate lung colorectal ovarian (PLCO)m2012 lung cancer prediction model better identify individuals for lung cancer screening compared with current US Preventive Services Task Force (USPSTF) criteria?
Knowledge Generated
- Using prediagnostic case and noncase sera from the PLCO Cancer Screening Trial data, a combined four-marker protein panel + PLCOm2012 model improved sensitivity by 11.9% and 9.9% and specificity by 12.9% and 6.9% compared with USPSTF2013 and the recent USPSTF2021 criteria, respectively.
Relevance
- A blood-based biomarker panel-PLCOm2012 combination significantly improves lung cancer risk assessment compared with USPSTF criteria.
Originally published at https://ascopubs.org
